Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16133577 | 0.95 | MGLL (0.35) | MGLLLMNACA12CA1CA2 | |
| SCHEMBL261924 | 0.95 | MGLL (0.35) | MGLLLMNACA12CA1CA2 | |
| SCHEMBL15502949 | 0.85 | MGLL (0.34) | MGLLKMT2AATM | |
| SCHEMBL12692621 | 0.84 | MGLL (0.35) | MGLLLMNAALDH1A1KMT2AATM | |
| SCHEMBL16938480 | 0.84 | ALDH1A1 (0.33) | LMNACA12CA1CA2CA3 | |
| SCHEMBL2607894 | 0.82 | MGLL (0.33) | MGLL | |
| SCHEMBL10075274 | 0.81 | SMN1; SMN2 (0.35) | MGLLALDH1A1KMT2AATM | |
| SCHEMBL2607898 | 0.81 | MGLL (0.32) | MGLL | |
| SCHEMBL26743643 | 0.81 | MGLL (0.32) | MGLLLMNACA12CA1CA2 | |
| SCHEMBL19704975 | 0.79 | MGLL (0.35) | MGLLALDH1A1KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014062856-A1 | HYPOXIA AND HYALURONAN AND MARKERS THEREOF FOR DIAGNOSIS AND MONITORING OF DISEASES AND CONDITIONS AND RELATED METHODS | HALOZYME, INC. (US) | 2014-04-24 | — | — | WO | claimed |
| US-10442845-B2 | Interferon analogs | BIORION TECHNOLOGIES B.V. (NL) | 2019-10-15 | — | — | US | disclosed |
| US-20180298075-A1 | Interferon Analogs | BIORION TECHNOLOGIES B.V. (NL) | 2018-10-18 | — | — | US | disclosed |
| EP-3186281-A1 | COMBINATION THERAPY WITH A HYALURONAN-DEGRADING ENZYME AND AN IMMUNE CHECKPOINT INHIBITOR | Halozyme, Inc. (US) | 2017-07-05 | — | — | EP | disclosed |
| US-20160297861-A1 | Interferon Analogs | BIORION TECHNOLOGIES B.V. (NL) | 2016-10-13 | — | — | US | disclosed |
| EP-2519250-B1 | Interferon analogs | BIORION TECHNOLOGIES B V (NL) | 2016-06-01 | — | — | EP | disclosed |
| WO-2016033555-A1 | COMBINATION THERAPY WITH A HYALURONAN-DEGRADING ENZYME AND AN IMMUNE CHECKPOINT INHIBITOR | HALOZYME, INC. (US) | 2016-03-03 | — | — | WO | disclosed |
| US-20130064791-A1 | Interferon Analogs | BIORION TECHNOLOGIES B.V. (NL) | 2013-03-14 | — | — | US | disclosed |
| EP-2519250-A1 | INTERFERON ANALOGS | Biorion Technologies B.V. (NL) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011081523-A1 | INTERFERON ANALOGS | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10442845-B2 | Interferon analogs | IFNAR1, IFNG, MAVS | MGLL 3529/4885LMNA 3122/4885CA12 4871/4885 |
| US-20180298075-A1 | Interferon Analogs | IFNAR1, IFNG, MAVS | MGLL 3529/4885LMNA 3122/4885CA12 4871/4885 |
| US-20130064791-A1 | Interferon Analogs | IFNAR1, IFNG, MAVS | MGLL 3529/4885LMNA 3122/4885CA12 4871/4885 |
| US-20160297861-A1 | Interferon Analogs | IFNAR1, IFNG, MAVS | MGLL 3529/4885LMNA 3122/4885CA12 4871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.